NCT/Study#
NCT06747585 /
ALE-P02-01
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors
DISEASE GROUP:
SCCs, Head & Neck, Lung and Cervical
current phase:
Phase I/II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
